Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$31.14
-$0.27(-0.85%)
At close: 4:00 PM EDT
$31.14
-$0.27(-0.85%)
Day’s Range― - ―
52-Week Range$17.00 - $35.83
Previous CloseN/A
Volume264.76K
Average Volume (3M)422.62K
Market Cap
$1.53B
Enterprise Value$1.28K
Total Cash (Recent Filing)$373.12M
Total Debt (Recent Filing)$351.00K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 18, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.68
Shares Outstanding49,307,728
10 Day Avg. Volume407,239
30 Day Avg. Volume422,623
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$44.63Price Target Upside43.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Expanding Asset BaseMinimal debt reduces fixed financial obligations and preserves flexibility to fund clinical development. The substantial increase in assets indicates strong capitalization, providing a more durable base for advancing the pipeline despite current operating losses.
Strategic ARR-002 PartnershipRegionalizing ARR-002 development and commercialization can reduce ArriVent’s execution burden while creating milestone and royalty opportunities. Retained rights outside Greater China preserve potential participation in additional markets as the asset develops.
Advancing Oncology PipelineMultiple clinical programs provide more than one route to future value creation. Pivotal firmonertinib trials target underserved uncommon EGFR-mutated NSCLC patients, while ADC programs broaden the pipeline and reduce reliance on a single asset.
Bears Say
No Commercial RevenueThe company has not yet demonstrated a revenue-generating commercial model, leaving future funding dependent on successful clinical development, partnerships or eventual product approval. This makes long-term financial progress highly contingent on pipeline execution.
Widening Net LossesLosses have expanded materially while revenue remains absent, showing that operating investment is rising faster than any offsetting income. Unless development spending produces approvals or partner economics, sustained losses could erode the capital base over time.
Persistent Cash BurnNegative operating and free cash flow means the business cannot currently fund operations internally. Even with reported funding into 2028, continued clinical spending creates ongoing dependence on external capital, partnerships or future commercialization proceeds.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $17.00 and its highest was $35.83 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.53B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 72 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Aug 12, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$0.063.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -1.04.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 49,307,728 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went down -4.641%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.63 (43.30% Upside)
$44.63 (43.30% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 100%
Sector Average 60%
Sector Average 60%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$44.63
▲(43.30% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
9.04% Insiders
11.43% Mutual Funds
56.67% Other Institutional Investors
11.13% Public Companies and
Individual Investors